Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KMHH-03
- Development stage
- Phase 1
- Lead developer
- Beijing Kangming Hanghui Biotechnology
- Administration
- Injectable
01
Overview
KMHH-03 is an investigational drug currently being studied as an injectable therapy for advanced breast cancer. The primary objectives of ongoing clinical trials are to evaluate the safety, tolerability, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single-dose administration in patients with advanced breast cancer. Secondary objectives include assessment of pharmacokinetic characteristics, immunogenicity, and preliminary efficacy to inform future dosing regimens and trial design. The drug is being developed by Beijing Kangming Hanghui Biotechnology[1].
Beyond the preview
Go deeper on KMHH-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KMHH-03.